[EN] 6-PHENYL-N-PHENYL-(1,3,5) -TRIAZINE-2,4-DIAMINE DERIVATIVES AND RELATED COMPOUNDS WITH LYSOPHPHOSPHATIDIC ACID ACYLTRANSFERASE BETA (LPAAT-BETA) INHIBITORY ACTIVITY FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DERIVES DE 6-PHENYL-N-PHENYL-(1,3,5)-TRIAZINE-2,4-DIAMINE ET COMPOSES APPARENTES AYANT UN EFFET INHIBITEUR DE L'ACIDE LYSOPHOSPHATIDIQUE ACYLTRANSFERASE BETA (LPAAT-BETA) ET DESTINES A ETRE UTILISES POUR TRAITER LE CANCER
申请人:CELL THERAPEUTICS INC
公开号:WO2003037346A1
公开(公告)日:2003-05-08
The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells, where R1-R5 are hydrogen or non-ydrogen substituents, and Q is a heteroatom or heteroatom attached to one or more methylene groups.
Aryl triazines as LPAAT-β inhibitors and uses thereof
申请人:Cell Therapeutics, Inc.
公开号:US07291616B2
公开(公告)日:2007-11-06
The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.
Novel nicotinoylbenzoguanamine derivatives represented by the general formula
as well as their acid addition salts are disclosed. These substances inhibit the reversed passive Arthus reaction and are useful in clinical fields as remedies for rheumatism and for allergic nephritis.